204 related articles for article (PubMed ID: 15564138)
1. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer.
Kaliberov SA; Kaliberova LN; Stockard CR; Grizzle WE; Buchsbaum DJ
Mol Ther; 2004 Dec; 10(6):1059-70. PubMed ID: 15564138
[TBL] [Abstract][Full Text] [Related]
2. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus.
Griffith TS; Broghammer EL
Mol Ther; 2001 Sep; 4(3):257-66. PubMed ID: 11545617
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line.
Zhang L; Gu J; Lin T; Huang X; Roth JA; Fang B
Gene Ther; 2002 Sep; 9(18):1262-70. PubMed ID: 12215894
[TBL] [Abstract][Full Text] [Related]
4. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
5. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Voelkel-Johnson C; King DL; Norris JS
Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
[TBL] [Abstract][Full Text] [Related]
6. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Vanoosten RL; Moore JM; Ludwig AT; Griffith TS
Mol Ther; 2005 Apr; 11(4):542-52. PubMed ID: 15771957
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
[TBL] [Abstract][Full Text] [Related]
8. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.
Kaliberov SA; Kaliberova LN; Buchsbaum DJ
Gene Ther; 2005 Mar; 12(5):407-17. PubMed ID: 15616600
[TBL] [Abstract][Full Text] [Related]
9. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
[TBL] [Abstract][Full Text] [Related]
10. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
Shankar S; Singh TR; Srivastava RK
Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.
Sanlioglu AD; Koksal IT; Karacay B; Baykara M; Luleci G; Sanlioglu S
Cancer Gene Ther; 2006 Jan; 13(1):21-31. PubMed ID: 16052230
[TBL] [Abstract][Full Text] [Related]
12. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
[TBL] [Abstract][Full Text] [Related]
13. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
[TBL] [Abstract][Full Text] [Related]
14. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
[TBL] [Abstract][Full Text] [Related]
15. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
Ren XW; Liang M; Meng X; Ye X; Ma H; Zhao Y; Guo J; Cai N; Chen HZ; Ye SL; Hu F
Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383
[TBL] [Abstract][Full Text] [Related]
16. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
17. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.
Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS
J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019
[TBL] [Abstract][Full Text] [Related]
18. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins.
Hu B; Zhu H; Qiu S; Su Y; Ling W; Xiao W; Qi Y
Biochem Biophys Res Commun; 2004 Dec; 325(4):1153-62. PubMed ID: 15555548
[TBL] [Abstract][Full Text] [Related]
19. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice.
Shi J; Zheng D; Liu Y; Sham MH; Tam P; Farzaneh F; Xu R
Cancer Res; 2005 Mar; 65(5):1687-92. PubMed ID: 15753363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]